Bxcl701 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bxcl701. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bxcl701 Today - Breaking & Trending Today

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA. ....

Vimal Mehta , Vincentj Oneill , Prostate Cancer Working Group , Product Development , Bioxcel Therapeutics Inc , Bioxcel Therapeutics , Onkosxcel Therapeutics , Cancers Symposium , Medical Officer , Xcel Therapeutics , Metastatic Small Cell Neuroendocrine Prostate Cancer ,

BioXcel Reports Positive OS Results From Phase 2 Trial Of BXCL701 In Patients With SCNC

BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company focused on neuroscience and immuno-oncology, announced Tuesday positive overall survival or OS data from its Phase 2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) in patients with small cell neuroendocrine prostate cancer or SCNC. ....

Vincent Oneill , Onkosxcel Therapeutics , More Such Health News , Bioxcel Therapeutics Inc , Bioxcel Therapeutics , Chief Rd Officer , Ositive Os , Atients With Scnc ,

BXCL701 Plus Pembrolizumab Generates Positive OS Data in Small Cell Neuroendocrine mCRPC

Treatment with the combination of the investigational oral innate immune activator BXCL701 and pembrolizumab led to a median overall survival of 13.6 months in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer. ....

Vincentj Oneill , Rahul Aggarwal , University Of California San Francisco , Prostate Cancer Working Group , Clinical Sciences , Helen Diller Family Comprehensive Cancer Center , California San Francisco , Cancers Symposium , Onkosxcel Therapeutics , Xcel Therapeutics , Small Cell Neuroendocrine Carcinoma , Castration Resistant Prostate Cancer ,

BXCL701 Plus Pembrolizumab Elicits Durable Responses in Small Cell Neuroendocrine mCRPC

The combination of BXCL701 and pembrolizumab produced durable responses in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to data from a phase 2a trial presented at the 2023 Genitourinary Cancers Symposium. ....

United States , San Francisco , Rahul Aggarwal , Clinical Sciences , Prostate Cancer Clinical Trials Working Group , University Of California , Helen Diller Family Comprehensive Cancer Center , Platinum Resistant Small Cell Neuroendocrine Carcinoma , Metastatic Castration Resistant Prostate Cancer , Phase 2a Trial Nct03910660 , 2023 Genitourinary Cancers Symposium ,

New Haven biotech to create new subsidiary focused on cancer drugs

BioXcel Therapeutics is creating a wholly-owned subsidiary focused on developing. ....

Vimal Mehta , Bioxcel Therapeutics , Onkosxcel Therapeutics , New Haven , Bioxcel Therapeutics , Us Food And Drug Administration , Phase 2 , Onkosxcel Therapeutics , T Insider , Or Bioxcel Therapeutics , Uther Turmelle Hearstmediact Com ,